Yaron Werber, an analyst from TD Cowen, maintained the Buy rating on Argenx Se. The associated price target was raised to $800.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yaron Werber has given his Buy rating due to a combination of factors including the strong performance of Argenx’s Vyvgart sales, which significantly exceeded expectations in the second quarter. The sales reached $949 million, surpassing both the consensus estimate of $866 million and investor expectations of around $900 million. This growth is driven by a higher gross price and increased volume, which are expected to offset higher discounts in Medicare Part D and commercial plans.
Moreover, Werber notes that the company is experiencing robust market expansion, with 15,000 patients globally on Vyvgart, including significant shares in CIDP and gMG. The company’s pipeline is also promising, with five Phase 3 catalysts expected by the end of 2026 and advancements in other products like empa and ARGX-119. These factors, combined with strong management and financial leverage, support the Buy rating and the new price target of $800.